Envveno Medical Corp (NVNO) Stock Price, Quote & News

Company Profile

enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops e...

Industry: Medical Devices

Sector: Healthcare

Phone: 949 261 2900

Website: www.envveno.com

Address:

70 Doppler, Irvine, United States

AncientIrmese Feb. 2 at 8:22 PM

$NVNO Stock Price Down??? Shocking!!!!

0 · Reply

Jordan1857 Feb. 2 at 6:06 PM

$NVNO Shaking weak hands.

0 · Reply

SkinnyDipping Jan. 30 at 9:00 PM

$ELPW All of these low float Asian tickers randomly running is well known scam to capture US dollars to stay afloat. They all have this in common. The insiders own most of the shares and rug it when they can’t halt it up anymore, taking chaser capital with them. If retail wants to run up low floats without worrying about rugs why not pick tickers like $NVNO ? 500k float and insiders only hold 20k shares. 🤦🏻‍♀️

0 · Reply

topstockalerts Jan. 30 at 8:23 PM

$NVNO Curling back up with buyers stepping in 📈. Momentum is building and price is starting to respond. This could be the start of another move.

0 · Reply

topstockalerts Jan. 30 at 7:49 PM

$NVNO Impressive strength showing today. Price refuses to pull back. Buyers remain aggressive 🔥.

1 · Reply

AncientIrmese Jan. 30 at 7:03 PM

$NVNO Get out while you can. Total scam here.

1 · Reply

Jordan1857 Jan. 30 at 5:42 PM

$NVNO legitime target could be 100$, 50$ is First target.

0 · Reply

Jordan1857 Jan. 28 at 6:07 PM

$NVNO almost locked.

0 · Reply

Stmkr Jan. 28 at 9:07 AM

$NVNO I realise they need to raise cash and big dilution is to be expected. But $7M market cap makes no sense at all. What is the bear thesis against enVVe? Here are my thoughts on NVNO https://open.substack.com/pub/biotechpharmainvestor/p/envveno-medical-nvno-not-just-an?utm_campaign=post-expanded-share&utm_medium=web

1 · Reply

Jordan1857 Jan. 27 at 4:00 PM

$NVNO I’m back here. 10$ average

0 · Reply

enVVeno Medical Announces Reverse Stock Split

Nov 26, 2025, 8:48 AM EST - 2 months ago

enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment

Nov 13, 2025, 5:00 PM EST - 2 months ago

enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve

Oct 31, 2025, 8:05 AM EDT - 3 months ago

enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Sep 26, 2025, 8:45 AM EDT - 4 months ago

enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment

Sep 15, 2025, 8:45 AM EDT - 5 months ago

enVVeno Medical Updates Regulatory Status of VenoValve(R)

Aug 20, 2025, 7:00 AM EDT - 6 months ago

enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)

Aug 15, 2025, 9:21 AM EDT - 6 months ago

enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 6, 2025, 8:30 AM EDT - 6 months ago

Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

Aug 4, 2025, 9:05 AM EDT - 6 months ago

enVVeno Medical Participates in a New Virtual Investor "What This Means" Segment to Discuss How President Trump's Recent CVI Diagnosis May Impact the Company

Aug 1, 2025, 8:00 AM EDT - 6 months ago

enVVeno Medical Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 22, 2025, 8:45 AM EDT - 7 months ago

enVVeno Medical Participates in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference

Jun 6, 2025, 8:05 AM EDT - 8 months ago

Positive Interim 2-Year Data from enVVeno Medical's VenoValve Pivotal Study to be Presented Today at the Society for Vascular Surgery (SVS) 2025 Vascular Annual Meeting

May 19, 2025, 8:05 AM EDT - 9 months ago

enVVeno Medical Appoints Jennifer Bright as Chief Financial Officer

May 13, 2025, 8:45 AM EDT - 9 months ago

Three-Year VenoValve(R) First-in-Human Trial Data Published in the Annals of Vascular Surgery

May 1, 2025, 8:05 AM EDT - 9 months ago

enVVeno Medical Reports First Quarter 2025 Financial Results and Reiterates Progress Toward VenoValve FDA Decision Expected in 2H24

Apr 23, 2025, 8:00 AM EDT - 10 months ago

VenoValve to be Featured During Presentation at the 47th Annual Charing Cross Symposium

Apr 16, 2025, 8:30 AM EDT - 10 months ago

enVVeno Medical to Participate in a Live Virtual Investor Closing Bell Segment

Mar 31, 2025, 9:00 AM EDT - 11 months ago

The Impact of the VenoValve(R) on Patients with Primary and Secondary Chronic Venous Insufficiency (CVI) to be Presented at the Society for Clinical Vascular Surgery 52nd Annual Symposium

Feb 28, 2025, 8:00 AM EST - 1 year ago

enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Feb 19, 2025, 9:00 AM EST - 1 year ago

enVVeno Medical Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 19, 2025, 8:45 AM EST - 1 year ago

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

Feb 7, 2025, 9:00 AM EST - 1 year ago

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Dec 16, 2024, 8:50 AM EST - 1 year ago

enVVeno Medical Successfully Completes Final Wave of Implants in Pre-Clinical GLP Study for enVVe

Nov 27, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical Highlights Successful 2024 VEITH Symposium with Launch of Recap Website

Nov 20, 2024, 8:30 AM EST - 1 year ago

enVVeno Medical to Present Definitive One Year Data from the VenoValve U.S. Pivotal Trial Today at the 51st Annual VEITH Symposium

Nov 19, 2024, 8:15 AM EST - 1 year ago

enVVeno Medical Submits the VenoValve PMA Application Seeking FDA Approval

Sep 24, 2021, 9:00 AM EDT - 4 years ago

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

Sep 22, 2021, 7:09 AM EDT - 4 years ago

Hancock Jaffe To Rebrand As enVVeno Medical

Sep 21, 2021, 4:00 PM EDT - 4 years ago

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

Sep 15, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe to Host Corporate Update Conference Call and Webcast on September 21, 2021

Sep 8, 2021, 7:43 PM EDT - 4 years ago

Hancock Jaffe Laboratories: Developing Nature-Mimetic Bioprosthetics

Sep 7, 2021, 8:05 AM EDT - 4 years ago

Hancock Jaffe Laboratories Announces $20 Million Registered Direct Offering Priced At-the-Market Under NASDAQ Rules

Aug 19, 2021, 11:49 AM EDT - 4 years ago

Hancock Jaffe Highlights Two-Year Data For Venous Insufficiency Valve

Aug 19, 2021, 8:00 AM EDT - 4 years ago

Hancock Jaffe Presents New Positive Two-Year VenoValve Data at the Society for Vascular Surgery Annual Meeting

Aug 3, 2021, 8:58 AM EDT - 4 years ago

Hancock Jaffe Stock Surges On FDA Breakthrough Designation For Its Venous Insufficiency Device

Aug 3, 2021, 8:05 AM EDT - 4 years ago

FDA Grants Breakthrough Device Designation Status for Hancock Jaffe's VenoValve

Jul 8, 2021, 9:05 AM EDT - 4 years ago

Hancock Jaffe to Present at the Ladenburg Thalmann 2021 Healthcare Conference

Apr 23, 2021, 12:40 PM EDT - 5 years ago

Hancock Jaffe Principal Investigator Dr. Jorge Hernando Ulloa Presents VenoValve One Year First-In-Human Data at Charing Cross International Symposium

Apr 7, 2021, 1:40 PM EDT - 5 years ago

First U.S. Patent Issues on Hancock Jaffe VenoValve

Apr 5, 2021, 7:30 AM EDT - 5 years ago

Hancock Jaffe Receives IDE Approval To Begin VenoValve U.S. Pivotal Trial

Mar 8, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Submits IDE Application to FDA for VenoValve U.S. Pivotal Trial

Jan 12, 2021, 8:30 AM EST - 5 years ago

Hancock Jaffe Concludes Successful VenoValve Pre-IDE Meeting with FDA

Dec 30, 2020, 4:15 PM EST - 5 years ago

Hancock Jaffe Announces Executive Promotions

Dec 21, 2020, 8:30 AM EST - 5 years ago

Hancock Jaffe Deemed Compliant With All NASDAQ Continued Listing Requirements

AncientIrmese Feb. 2 at 8:22 PM

$NVNO Stock Price Down??? Shocking!!!!

0 · Reply

Jordan1857 Feb. 2 at 6:06 PM

$NVNO Shaking weak hands.

0 · Reply

SkinnyDipping Jan. 30 at 9:00 PM

0 · Reply

topstockalerts Jan. 30 at 8:23 PM

$NVNO Curling back up with buyers stepping in 📈. Momentum is building and price is starting to respond. This could be the start of another move.

0 · Reply

topstockalerts Jan. 30 at 7:49 PM

$NVNO Impressive strength showing today. Price refuses to pull back. Buyers remain aggressive 🔥.

1 · Reply

AncientIrmese Jan. 30 at 7:03 PM

$NVNO Get out while you can. Total scam here.

1 · Reply

Jordan1857 Jan. 30 at 5:42 PM

$NVNO legitime target could be 100$, 50$ is First target.

0 · Reply

Jordan1857 Jan. 28 at 6:07 PM

$NVNO almost locked.

0 · Reply

Stmkr Jan. 28 at 9:07 AM

1 · Reply

Jordan1857 Jan. 27 at 4:00 PM

$NVNO I’m back here. 10$ average

0 · Reply

Icemanja Jan. 27 at 3:59 PM

$NVNO Paying a full-blown commercialization team, with no product, is a great way to show management commitment to preserve investor capital after wiping out over 90 million of investors captial. This management team is completely lost , and does not have what it takes to run or turn this company around. Even if they post positive results with the new product, only the few new retail investors who didn't do their DD will believe anything they say. The only value will be added to the MC is first round of 50 mil dilution. When everyone thought Venovalve was a home run, every PR was a sell-off, the only difference will be that every PR will be a nose-dive. #hashtagBermanEffect

2 · Reply

Golibajje Jan. 23 at 5:09 PM

$NVNO 4150 shares at $10.37 avg! loving it!!

2 · Reply

bigJacksonExtreme Jan. 22 at 10:44 PM

$NVNO Just checked back in after not looking at my stocks for years! Saw it was at 10 dollars! However, I then saw that lost 11k and the stock was diluted again for the 50th time. Now I only have 39.46 shares that have average cost of 312!!! Hahaha

0 · Reply

haupman Jan. 22 at 9:12 PM

$NVNO $9 is the low for the next 6 months.

0 · Reply

Icemanja Jan. 22 at 3:46 PM

$NVNO Ladenburg Thalmann & Co has 50mil worth of shares to sell , see you at 4.

1 · Reply

Golibajje Jan. 22 at 3:27 PM

$NVNO This will run like $PAVM $SLGB - $31M cash! - 655k shares after RS.. - Market cap is $6.5M!! LOW FLOAT and Trading over 1/4th of cash!!!

2 · Reply

Sookie1962 Jan. 22 at 3:08 AM

$NVNO

0 · Reply

Icemanja Jan. 21 at 4:28 PM

$NVNO enVVeno Medical Launches $50M Equity Offering Program https://www.theglobeandmail.com/investing/markets/stocks/NVNO/pressreleases/35837464/envveno-medical-launches-50m-equity-offering-program/ 7Mil MC and they have 50Mil to dilute. Hold on to your socks Berman needs that money in his bank account.

1 · Reply

Jordan1857 Jan. 21 at 4:15 PM

$NVNO under 9 can be a great entry point. Waiting a little for buying it.

1 · Reply

BOOGEYMAN_TRADEZ Jan. 21 at 2:33 PM

$NVNO next $PAVM . 570K float , 43$ a share in cash with little to no debt.

1 · Reply

Sookie1962 Jan. 21 at 12:36 PM

$NVNO do have options for already??just curious help please

0 · Reply

Sookie1962 Jan. 21 at 12:34 PM

$NVNO

0 · Reply

Market Cap	7.82M
Revenue (ttm)	0.00
Net Income (ttm)	-21.82M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	8,913
Avg Vol	19,781
Day's Range	N/A - N/A
Shares Out	656,000.00
Stochastic %K	27%
Beta	1.04
Analysts	Hold
Price Target	$12.50